Centralized Switch Can Be Improved Via Practice, Practical Strategy
This article was originally published in The Tan Sheet
Executive Summary
Over-the-counter drug makers can advance the EU centralized switch process by keeping the applications coming so that health authorities can "learn by doing," says Patrick Le Courtois, head of the human medicines development and evaluation unit at the European Medicines Agency
You may also be interested in...
European OTC Switch Still Muted By Regulatory Resistance
OTC sales growth is stifled by the EU’s “extremely restricted” switch evaluation process, says AESGP Director General Hubertus Cranz. But while prescription revenues shrink as governments tighten budgets, the OTC market is not hampered in this way.
European OTC Switch Still Muted By Regulatory Resistance
OTC sales growth is stifled by the EU’s “extremely restricted” switch evaluation process, says AESGP Director General Hubertus Cranz. But while prescription revenues shrink as governments tighten budgets, the OTC market is not hampered in this way.
European OTC Switch Still Muted By Regulatory Resistance
OTC sales growth is stifled by the EU’s “extremely restricted” switch evaluation process, says AESGP Director General Hubertus Cranz. But while prescription revenues shrink as governments tighten budgets, the OTC market is not hampered in this way.